Bedrijf laden
Just reported
Q3 2026 results
From Edwards Lifesciences's results release of 4 november 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 1,72B
+10% y/y
-1,5% q/qGuided
US$ 1,67B
midpoint
Above guide+2,7%EPS, GAAP
Actual
US$ 0,53
+6,0% y/y
+26% q/qGuided
—
No guide given
Operating income, GAAP
Actual
US$ 299,1M
-2,6% y/y
-42% q/qGuided
—
No guide given
Company outlook
Q4 2026
- RevenueUS$ 1,67B – US$ 1,75B+8,9% y/y First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Edwards Lifesciences is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plcUS$ 129,2BA+
SYKStryker Corp.US$ 118,9BA+
GEHCGE Healthcare Technologies Inc.US$ 37BA
GKOSGlaukos CorpUS$ 14,6BA
PENPenumbra, IncUS$ 12,6BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 okt 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 okt 2026BAGraded B, now A- GEHCGE Healthcare Technologies Inc.28 okt 2026CAGraded C, now A
Hoe het geld verdient
- Catheter-delivered aortic valve replacement72%
- Catheter-delivered mitral and tricuspid valve repair and replacement11%
- Surgical heart valve products16%
De omzetaandelen zijn schattingen voor nine months ended September 30, 2026, geen cijfers uit een ingediend rapport.
Concurreert met
Wat het verkoopt5
SAPIEN
A family of tissue valves delivered through a catheter to replace a diseased aortic valve; some systems are also used for pulmonary valve replacement.
PASCAL
A catheter-delivered device that helps bring together the leaflets of a leaking mitral or tricuspid valve.
EVOQUE
A tissue valve delivered through a catheter to replace a leaking tricuspid valve.
Nog 2 tonen
SAPIEN M3
A tissue valve delivered through a catheter to replace a diseased mitral valve.
INSPIRIS RESILIA, KONECT RESILIA, and MITRIS RESILIA
Surgical tissue valve products for aortic and mitral valve replacement; KONECT is a tissue valve conduit used in complex combined procedures.
Wie het koopt3
- Hospitals and health systems buy devices directly from Edwards sales teams or through distributors; in the United States, sales are mainly direct.
- Hospital purchasing groups and healthcare networks negotiate supplier contracts on behalf of hospitals.
- Heart specialists, including cardiac surgeons and interventional cardiologists, use the devices and take part in choosing treatments.
Waar het op steunt, en wat het kan breken
Waar het bedrijf van afhangt
- 1A large part of the business depends on hospitals adopting catheter-delivered aortic valve replacement and on clinicians choosing Edwards devices.
- 2Sales depend in part on government and private insurers covering procedures and paying hospitals enough to support their use.
- 3Some materials and components come from single-source suppliers; switching critical suppliers can require lengthy regulatory review.
- 4The company relies on clinical studies and regulatory clearances or approvals to bring devices to market and expand their permitted uses.
Wat er mis kan gaan
- 1If clinical studies do not show the needed results, or regulators do not approve new devices or uses, Edwards may be unable to sell those products or expand their use.
- 2Manufacturing, quality, safety, or delivery problems at Edwards or its suppliers could interrupt access to implanted heart valves and other devices.
- 3If insurers or government health programs restrict coverage or reduce payments, hospitals may buy fewer devices or seek lower prices.
Over Edwards Lifesciences Corporation
Edwards makes devices that replace or repair damaged heart valves. Some are delivered through a catheter, a thin tube passed through a blood vessel, while others are implanted during open-heart surgery. Hospitals and heart specialists use these devices to treat diseases affecting the aortic, mitral, and tricuspid valves.
- Hoofdkantoor
- Irvine, California, United States
- Opgericht in
- 1958
- Medewerkers
- Approximately 16,000 (December 31, 2025, medium)
- Genoteerd aan
- New York Stock Exchange
- Einde boekjaar
- December 31
Gebouwd uit de eigen deponeringen van Edwards Lifesciences Corporation bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.
